Prognostic value of minimal residual disease and polyclonal plasma cells in myeloma patients achieving a complete response to therapy.

Am J Hematol 2019 Jul 30;94(7):751-756. Epub 2019 Apr 30.

Division of Hematology, Mayo Clinic, Rochester, Minnesota.

Achievement of a complete response has been associated with improved outcomes in patients with multiple myeloma. Recently, increasing application of minimal residual disease (MRD) assessment has shown that MRD negativity is a powerful prognostic factor for survival outcomes. We wanted to examine the impact of the polyclonal plasma cell (pPC) compartment among patients in complete response (CR) but are MRD positive. This is a retrospective cohort study where 460 myeloma patients were identified who met criteria for CR and had multicolor flow cytometry performed on the bone marrow (BM). Monoclonal and pPCs were estimated during MRD testing. Final outcomes including overall survival (OS) and time to next treatment (TTNT) were compared among the groups. The median OS for the entire cohort was not reached (95% CI; 63 mos, NR) and the median TTNT was 31 months (95% CI; 27,36). Among the MRD group, median TTNT was 37.6 months vs 23 months for MRD patients (P < .001); the median OS was not reached for either group, but there was a trend toward better survival for MRD patients. Among the MRD group, median percentage of pPCs was 65% (2.5-98.5), and those with >95% pPCs had a significantly better TTNT (NR vs 23 months; P = .02) and a trend toward better OS. We conclude that achievement of MRD negativity predicts for better response durability and trend toward improved OS and an increased proportion of pPC predicts for better outcomes within those who have residual tumor cells highlighting the importance of marrow normalization.

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25481
Publisher Site
http://dx.doi.org/10.1002/ajh.25481DOI Listing
July 2019
27 Reads

Publication Analysis

Top Keywords

complete response
12
mrd
9
polyclonal plasma
8
median ttnt
8
trend better
8
ttnt months
8
mrd group
8
group median
8
predicts better
8
mrd negativity
8
minimal residual
8
mrd patients
8
residual disease
8
myeloma patients
8
patients
6
median
5
better
5
reached 95%
4
cohort reached
4
median entire
4

References

(Supplied by CrossRef)
Minimal residual disease in multiple myeloma
Munshi NC et al.
J Clin Oncol 2013

Similar Publications